Details of the Drug Combinations

General Information of This Drug (ID: DMNLQHK)

• Drug Name: Tanespimycin (DMNLQHK)
• Synonyms: CNF-101; [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; 17AAG, Tanespimycin, Geldanamycin, NSC330507, 17-(Allylamino)-17-demethoxygeldanamycin, CP 127374

Indication

Breast cancer; ICD 11: 2C60-2C65; Status: Phase 2 [1]; Multiple myeloma; ICD 11: 2A83; Status: Discontinued in Phase 3 [1]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Tanespimycin + Ruxolitinib	DC3A9WO	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[2]

7 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Belinostat + Tanespimycin	DC7DYOW	Belinostat	Adult Nasal Type Extranodal NK/T-cell Lymphoma	[3]
Docetaxel + Tanespimycin	DCDGRBZ	Docetaxel	Recurrent Prostate Cancer	[4]
Paclitaxel + Tanespimycin	DCUF85X	Paclitaxel	Unspecified Adult Solid Tumor, Protocol Specific	[5]
Tanespimycin + Bortezomib	DC33OQI	Bortezomib	Adult Acute Basophilic Leukemia	[6]
Tanespimycin + Irinotecan	DCFUQZM	Irinotecan	Unspecified Adult Solid Tumor, Protocol Specific	[7]
Tanespimycin + Cytarabine	DCI34DL	Cytarabine	Accelerated Phase Chronic Myelogenous Leukemia	[8]
Tanespimycin + Bortezomib	DCQQSXX	Bortezomib	Adult Grade III Lymphomatoid Granulomatosis	[9]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7751).
• [2] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [3] ClinicalTrials.gov (NCT00354185) PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
• [4] ClinicalTrials.gov (NCT00058253) Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
• [5] ClinicalTrials.gov (NCT00087217) 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
• [6] ClinicalTrials.gov (NCT00103272) 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
• [7] ClinicalTrials.gov (NCT00119236) 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
• [8] ClinicalTrials.gov (NCT00098423) Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
• [9] ClinicalTrials.gov (NCT00096005) Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas